Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group

Background : ENA is a selective inhibitor of IDH2 approved in the US for the treatment of patients with relapsed/refractory IDH2 mutated AML. Little is known on its efficacy in patients with IDH2m myelodysplastic syndromes. Here we report the preliminary results of a Phase 2 study evaluating the saf...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2021-11, Vol.138 (Supplement 1), p.63-63
Hauptverfasser:	Ades, Lionel, Dimicoli-Salazar, Sophie, Sebert, Marie, Cluzeau, Thomas, Stamatoulas Bastard, Aspasia, Laribi, Kamel, Fossard, Gaelle, Itzykson, Raphael, Beyne Rauzy, Odile, Garnier, Alice, Gloaguen, Silke, Vey, Norbert, Le Jeune, Caroline, Giagounidis, Aristoteles, Gyan, Emmanuel, Perard, Baptiste, Thepot, Sylvain, Ojeda, Mario, Chermat, Fatiha, Desseaux, Kristell, Clappier, Emmanuelle, Chevret, Sylvie, Platzbecker, Uwe, Fenaux, Pierre
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!